EMA starts evaluating use of Comirnaty, COVID-19 vaccine, in young people aged 12 to 15

Comirnaty is currently authorised for use in ages 16 and older. EMA’s CHMP will carry out an accelerated assessment of data submitted, including results from a large ongoing clinical study involving adolescents from 12 years of age.

Source:

European Medicines Agency